Zhou Rong, Schlam Roxana F, Yin Shawn, Gandhi Rajesh B, Adams Monica L
Department of Drug Product Science & Technology, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, NJ 08903.
PDA J Pharm Sci Technol. 2012 May-Jun;66(3):221-35. doi: 10.5731/pdajpst.2012.00861.
Saccharides, including sucrose, trehalose, mannitol, and sorbitol, are commonly employed as stabilizers, cryoprotectants, and/or tonicity adjusters in protein formulations. During the thawing of a protein-containing formulated bulk drug substance conducted prior to a drug product (DP) filling operation, a white, crystalline precipitate was observed. In addition, upon thawing, vial breakage was observed for filled DP that had been previously frozen at -40 °C. To investigate the causes of both phenomena, the freeze/thaw behavior of the formulation components was studied. Multiple physical characterization techniques, including differential scanning calorimetry (DSC), electrical resistance measurements, thermomechanical analysis (TMA), and powder X-ray diffraction (PXRD), were utilized to characterize the formulations. The PXRD pattern of precipitate collected from thawed bulk was consistent with that of a mannitol control. An exothermic transition observed by DSC, a sharp increase in electrical resistance detected via resistivity measurements, and the onset of volumetric expansion of the frozen matrix evident in the TMA curve offer evidence that the frozen mannitol solution undergoes transitions at or near the vial breakage temperature (-22 to -23 °C) observed during warming. In addition, osmolality measurements taken from fractionated aliquots of frozen samples indicated that non-uniform concentration gradients contributed to precipitation of mannitol observed at larger scales. Small-scale laboratory experiments (i.e., 10-125 mL) failed to adequately predict behavior at larger scale (i.e., in 1 L and 2 L bottles). Upon linking the detrimental behavior to the freeze/thaw properties of the tonicity adjustor, mannitol, alternative saccharide excipients, including sorbitol, sucrose, and trehalose, were evaluated at isotonic concentrations over a temperature range of -80 to 25 °C using physical-chemical techniques and visual observation. Neither precipitation nor vial breakage was observed for the alternate saccharides. Recommendations for saccharide selection are provided based on storage conditions and scale considerations for liquid biopharmaceutical formulations.
Saccharides, including sucrose, trehalose, mannitol, and sorbitol, are commonly employed as stabilizers, cryoprotectants and/or tonicity adjusters in protein formulations. During thawing of formulated bulk drug substance, a white, crystalline precipitate was observed. In addition, upon thawing, vial breakage was observed for filled drug product that had been previously frozen at -40 °C. To investigate the causes of both phenomena, multiple physical characterization techniques were utilized to characterize the formulations. The powder X-ray diffraction pattern of precipitate collected from thawed bulk was consistent with that of a mannitol control. Upon linking the detrimental behavior to the freeze/thaw properties of the tonicity adjustor, mannitol, alternative saccharide excipients, including sorbitol, sucrose, and trehalose, were evaluated at isotonic concentrations over a temperature range of -80 to 25 °C using physico-chemical techniques and visual observation. Neither precipitation nor vial breakage was observed for the alternate saccharides. Recommendations for saccharide selection are given based on storage conditions and scale considerations for liquid biopharmaceutical formulations.
糖类,包括蔗糖、海藻糖、甘露醇和山梨醇,通常在蛋白质制剂中用作稳定剂、冷冻保护剂和/或渗透压调节剂。在药品(DP)灌装操作前对含蛋白质制剂的原料药进行解冻时,观察到白色结晶沉淀。此外,解冻时,先前在-40°C冷冻的已灌装DP出现了小瓶破裂。为了研究这两种现象的原因,对制剂成分的冻融行为进行了研究。利用多种物理表征技术,包括差示扫描量热法(DSC)、电阻测量、热机械分析(TMA)和粉末X射线衍射(PXRD)对制剂进行表征。从解冻的原料药中收集的沉淀的PXRD图谱与甘露醇对照的图谱一致。DSC观察到的放热转变、通过电阻率测量检测到的电阻急剧增加以及TMA曲线中明显的冷冻基质体积膨胀的开始,提供了证据表明冷冻的甘露醇溶液在升温过程中在观察到的小瓶破裂温度(-22至-23°C)或接近该温度时发生转变。此外,对冷冻样品的分份等分试样进行的渗透压测量表明,不均匀的浓度梯度导致了在较大规模上观察到的甘露醇沉淀。小规模实验室实验(即10-125 mL)未能充分预测较大规模(即1 L和2 L瓶)下的行为。在将有害行为与渗透压调节剂甘露醇的冻融特性联系起来后,使用物理化学技术和目视观察,在-80至25°C的温度范围内对等渗浓度的替代糖类辅料,包括山梨醇、蔗糖和海藻糖进行了评估。替代糖类均未观察到沉淀或小瓶破裂。根据液体生物制药制剂的储存条件和规模考虑,提供了糖类选择的建议。
糖类,包括蔗糖、海藻糖、甘露醇和山梨醇,通常在蛋白质制剂中用作稳定剂、冷冻保护剂和/或渗透压调节剂。在制剂原料药解冻过程中,观察到白色结晶沉淀。此外,解冻时,先前在-40°C冷冻的已灌装药品出现了小瓶破裂。为了研究这两种现象的原因,利用多种物理表征技术对制剂进行表征。从解冻的原料药中收集的沉淀的粉末X射线衍射图谱与甘露醇对照的图谱一致。在将有害行为与渗透压调节剂甘露醇的冻融特性联系起来后,使用物理化学技术和目视观察,在-80至25°C的温度范围内对等渗浓度的替代糖类辅料,包括山梨醇、蔗糖和海藻糖进行了评估。替代糖类均未观察到沉淀或小瓶破裂。根据液体生物制药制剂的储存条件和规模考虑,给出了糖类选择的建议。